TrialBlood2002

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

John C Byrd et al.PubMed ↗Publisher ↗

No numbers read from the abstract.